Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236146 | 0.80 | MGLL (0.47) | MGLLCA12CA7CA14 | |
| SCHEMBL19878897 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL28019904 | 0.77 | MGLL (0.44) | MGLLCA12CA7CA14 | |
| SCHEMBL42534 | 0.72 | KDM4E (0.50) | CA12 | |
| SCHEMBL41955 | 0.71 | — | — | |
| SCHEMBL2920270 | 0.71 | — | — | |
| SCHEMBL170249 | 0.71 | TSHR (0.40) | MGLLCA12CA7CA14 | |
| SCHEMBL6300105 | 0.71 | TSHR (0.43) | MGLLCA12CA7CA14 | |
| SCHEMBL2918371 | 0.69 | — | — | |
| SCHEMBL31348042 | 0.69 | ALDH1A1 (0.44) | MGLLCA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | claimed |
| WO-2008098143-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | WO | claimed |
| WO-2008002575-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20070299062-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
| WO-2002023784-A2 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | claimed |
| EP-0107261-B1 | (2-((NITROPYRIDINYL)AMINO)PHENYL)ARYLMETHANONES AND SALTS, THEIR USE IN MEDICINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF (2-((AMINOPYRIDINYL)AMINO)PHENYL)ARYLMETHANONES AND PYRIDO(1,4)BENZODIAZEPINES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-09-21 | — | — | EP | claimed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008098143-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008002575-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299062-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2002023784-A2 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
| EP-0107261-B1 | (2-((NITROPYRIDINYL)AMINO)PHENYL)ARYLMETHANONES AND SALTS, THEIR USE IN MEDICINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF (2-((AMINOPYRIDINYL)AMINO)PHENYL)ARYLMETHANONES AND PYRIDO(1,4)BENZODIAZEPINES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ABCB11, FPR1, C5 | MGLL 565/4885ADRA2A 4322/4885ADRA2B 3714/4885 |
| US-20070299062-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC4R | MGLL 475/4885ADRA2A 161/4885ADRA2B 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.